​

TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TMDX Stock Forecast

TransMedics Group (TMDX) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $143.80, with a high of $166.00 and a low of $130.00. This represents a 29.63% increase from the last price of $110.93.

$50 $80 $110 $140 $170 $200 High: $166 Avg: $143.8 Low: $130 Last Closed Price: $110.93

TMDX Stock Rating

TransMedics Group stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (75.00%), 3 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 3 9 Strong Sell Sell Hold Buy Strong Buy

TMDX Price Target Upside V Benchmarks

TypeNameUpside
StockTransMedics Group29.63%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks31.62%

Price Target Trends

1M3M12M
# Anlaysts-19
Avg Price Target-$130.00$146.00
Last Closing Price$110.93$110.93$110.93
Upside/Downside-17.19%31.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26272--11
Mar, 26273--12
Feb, 26273--12
Jan, 26273--12
Dec, 25273--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026Stifel Nicolaus$130.00$134.77-3.54%17.19%
Dec 17, 2025Canaccord Genuity$148.00$125.0418.36%33.42%
Dec 08, 2025Needham$166.00$136.5121.60%49.64%
Dec 02, 2025Morgan Stanley$135.00$150.42-10.25%21.70%
Oct 30, 2025Matt O'BrienPiper Sandler$140.00$134.324.23%26.21%
Oct 30, 2025Jason MillsCanaccord Genuity$147.00$134.329.44%32.52%
Oct 23, 2025Needham$148.00$119.5423.81%33.42%
Oct 13, 2025Jefferies$145.00$107.2935.15%30.71%
Oct 07, 2025Evercore ISI$155.00$113.9336.05%39.73%
Dec 11, 2024David RescottRobert W. Baird$120.00$67.3678.15%8.18%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 16, 2026Cowen & Co.BuyBuyhold
Dec 22, 2025Piper SandlerOverweightOverweighthold
Dec 08, 2025NeedhamBuyBuyhold
Oct 30, 2025Piper SandlerOverweightOverweighthold
Oct 30, 2025Canaccord GenuityBuyBuyhold
Oct 30, 2025NeedhamBuyBuyhold
Oct 23, 2025NeedhamBuyBuyupgrade
Oct 13, 2025JefferiesBuyinitialise
Sep 16, 2025Evercore ISIOutperforminitialise
Jun 17, 2025OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.60$-1.23$-0.77$1.07$5.60---
Avg Forecast$-1.58$-1.33$-0.93$0.98$1.47$2.38$2.91$3.71
High Forecast$-1.46$-1.30$-0.90$1.05$1.70$2.72$2.95$3.76
Low Forecast$-1.69$-1.34$-0.96$0.91$1.17$1.72$2.84$3.62
Surprise %1.27%-7.52%-17.20%9.18%280.95%---

Revenue Forecast

$0 $190M $380M $570M $760M $950M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$30.26M$93.46M$241.62M$441.54M$605.49M---
Avg Forecast$28.29M$86.22M$228.47M$429.57M$524.07M$635.61M$787.30M$923.65M
High Forecast$29.87M$87.01M$230.40M$430.57M$529.01M$636.81M$798.35M$933.95M
Low Forecast$26.74M$84.84M$226.23M$428.45M$517.83M$634.40M$776.25M$906.76M
Surprise %6.98%8.39%5.76%2.79%15.54%---

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-44.22M$-36.23M$-25.03M$35.46M$190.29M---
Avg Forecast$-33.47M$-36.82M$-35.78M$32.64M$48.33M$84.88M$92.50M$120.48M
High Forecast$-26.78M$-29.46M$-28.62M$34.10M$55.13M$88.42M$96.00M$122.22M
Low Forecast$-40.17M$-44.18M$-42.93M$29.64M$38.09M$56.06M$92.38M$117.61M
Surprise %32.09%-1.60%-30.05%8.66%293.77%---

TMDX Forecast FAQ

Is TransMedics Group stock a buy?

TransMedics Group stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TransMedics Group is a favorable investment for most analysts.

What is TransMedics Group's price target?

TransMedics Group's price target, set by 12 Wall Street analysts, averages $143.8 over the next 12 months. The price target range spans from $130 at the low end to $166 at the high end, suggesting a potential 29.63% change from the previous closing price of $110.93.

How does TransMedics Group stock forecast compare to its benchmarks?

TransMedics Group's stock forecast shows a 29.63% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (31.62%).

What is the breakdown of analyst ratings for TransMedics Group over the past three months?

  • April 2026: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 58.33% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is TransMedics Group’s EPS forecast?

TransMedics Group's average annual EPS forecast for its fiscal year ending in December 2026 is $2.38, marking a -57.50% decrease from the reported $5.6 in 2025. Estimates for the following years are $2.91 in 2027, and $3.71 in 2028.

What is TransMedics Group’s revenue forecast?

TransMedics Group's average annual revenue forecast for its fiscal year ending in December 2026 is $635.61M, reflecting a 4.97% increase from the reported $605.49M in 2025. The forecast for 2027 is $787.3M, and $923.65M for 2028.

What is TransMedics Group’s net income forecast?

TransMedics Group's net income forecast for the fiscal year ending in December 2026 stands at $84.88M, representing a -55.40% decrease from the reported $190.29M in 2025. Projections indicate $92.5M in 2027, and $120.48M in 2028.